NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) R
Post# of 111
(Total Views: 175)
Posted On: 09/16/2022 3:47:47 PM
NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Pricing of Public Offering
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares of its common stock. According to the announcement, the combined offering price will be $6 per share (or common stock equivalent) and associated warrants. The company noted that in addition to the $6 per share exercise price, the warrants will be immediately exercisable with an expiration date five years following the date of issuance. Aditxt anticipates the offering to close on or about Sept. 20, 2022, with H.C. Wainwright & Co. acting as exclusive placement agent for the offering. Based on the pricing, expected gross proceeds from the offering should reach an estimated $20 million, which Aditxt plans to use for general corporate purposes, including R&D, capital expenditures, working capital and general and administrative expenses as well as potential acquisitions or investments.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares of its common stock. According to the announcement, the combined offering price will be $6 per share (or common stock equivalent) and associated warrants. The company noted that in addition to the $6 per share exercise price, the warrants will be immediately exercisable with an expiration date five years following the date of issuance. Aditxt anticipates the offering to close on or about Sept. 20, 2022, with H.C. Wainwright & Co. acting as exclusive placement agent for the offering. Based on the pricing, expected gross proceeds from the offering should reach an estimated $20 million, which Aditxt plans to use for general corporate purposes, including R&D, capital expenditures, working capital and general and administrative expenses as well as potential acquisitions or investments.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)ADiTx Therapeutics Inc. (ADTX) Stock Research Links
Scroll down for more posts ▼